TENOFOVIR ALAFENAMIDE FUMARATE Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Tenofovir Alafenamide Fumarate, and when can generic versions of Tenofovir Alafenamide Fumarate launch?
Tenofovir Alafenamide Fumarate is a drug marketed by Apotex and is included in one NDA.
The generic ingredient in TENOFOVIR ALAFENAMIDE FUMARATE is tenofovir alafenamide fumarate. There are forty-two drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the tenofovir alafenamide fumarate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Tenofovir Alafenamide Fumarate
A generic version of TENOFOVIR ALAFENAMIDE FUMARATE was approved as tenofovir alafenamide fumarate by APOTEX on March 21st, 2024.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for TENOFOVIR ALAFENAMIDE FUMARATE?
- What are the global sales for TENOFOVIR ALAFENAMIDE FUMARATE?
- What is Average Wholesale Price for TENOFOVIR ALAFENAMIDE FUMARATE?
Summary for TENOFOVIR ALAFENAMIDE FUMARATE
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 113 |
| Clinical Trials: | 82 |
| Patent Applications: | 228 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for TENOFOVIR ALAFENAMIDE FUMARATE |
| DailyMed Link: | TENOFOVIR ALAFENAMIDE FUMARATE at DailyMed |
Recent Clinical Trials for TENOFOVIR ALAFENAMIDE FUMARATE
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Assistance Publique - Hôpitaux de Paris, FRANCE | Phase 3 |
| Ministry of Health, Thailand | Phase 3 |
| Chiang Mai University, Thailand | Phase 3 |
Anatomical Therapeutic Chemical (ATC) Classes for TENOFOVIR ALAFENAMIDE FUMARATE
Paragraph IV (Patent) Challenges for TENOFOVIR ALAFENAMIDE FUMARATE
| Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
|---|---|---|---|---|---|---|
| VEMLIDY | Tablets | tenofovir alafenamide fumarate | 25 mg | 208464 | 6 | 2019-11-05 |
US Patents and Regulatory Information for TENOFOVIR ALAFENAMIDE FUMARATE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apotex | TENOFOVIR ALAFENAMIDE FUMARATE | tenofovir alafenamide fumarate | TABLET;ORAL | 213867-001 | Mar 21, 2024 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
